Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers

NCT06854783 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-02-04

No results posted yet for this study

Summary

The purpose of this study is to assess the pharmacokinetics, safety, tolerability and food effect of investigational drug MRX1 in healthy adults.

Conditions

  • Pharmacokinetics

Interventions

DRUG

Cannabidiol

Cannabidiol

Sponsors & Collaborators

  • Ananda Pharma plc

    collaborator UNKNOWN
  • Tiamat Australia Pty Ltd

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-14
Primary Completion
2025-10-01
Completion
2025-10-01

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06854783 on ClinicalTrials.gov